{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-025175","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.011143+00:00","generated_at":"2026-05-31T11:58:59.489890+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"GeoVax reports Q2 net loss of $5.1M; awarded up to $388M BARDA contract for COVID vaccine trial","bullets":["Net loss $5.1M ($1.99/share) vs $5.9M ($3.79) in Q2 2023; R&D expenses $4.3M.","BARDA Project NextGen award for GEO-CM04S1 Phase 2b trial; total value $367-388M incl. Allucent.","Cash $1.56M at June 30, 2024, down from $6.45M at Dec 31, 2023.","Gedeptin advanced to expanded Phase 2 trial for head and neck cancer; activation H1 2025.","Commercial manufacturing platform for GEO-CM04S1 established with Oxford Biomedica."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-025175","json":"https://secwatch.observer/filing/0001437749-24-025175.json","markdown":"https://secwatch.observer/filing/0001437749-24-025175.md","text":"https://secwatch.observer/filing/0001437749-24-025175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774924025175/0001437749-24-025175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774924025175/govx20240806_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:58:59.489890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}